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doi:10.1016/j.ejvs.2010.11.024Abstract Objectives: The study aimed to investigate early and long-term outcome of
thoracic endovascular aortic repair (TEVAR) for acute complicated type B dissection.
Design: This was a retrospective, single-centre, consecutive case series.
Materials and Methods: During the period 1999e2009, TEVAR was carried out in 50 patients
with non-traumatic acute complicated type B dissection, and in another 10 patients with acute
complications, including rupture, end-organ ischaemia and acute dilatation during the primary
hospitalisation, but >14 days after onset of symptoms. Thus, in total, 60 patients were
included; 22 with a DeBakey type IIIa dissection and 38 with a type IIIb; median age was 67
years. Early (30-day) and long-term (5-year) survival, re-intervention rate and complications
were recorded until 1 July 2010.
Results: Within 30 days, two (3%) deaths, one (2%) paraplegia and three (5%) strokes were
observed. Five-year survival was 87% and freedom from re-intervention at 5 years was 65%.
Conclusions: In patients with acute complicated type B aortic dissection, TEVAR can be per-
formed with excellent early and long-term survival, whereas morbidity and long-term dura-
bility must be further elucidated.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Acute aortic dissection is a potentially deleterious and highly
challenging condition. The classification of aortic dissection
is based on location of the entry tear and time from onset.
The Stanford classification distinguishes between type A andeducation questions on this pape
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ty for Vascular Surgery. PublisheB; a type A dissection includes the ascending aorta, and type
B originates in the descending aorta.1 The DeBakey classifi-
cation is a further subdivision, dividing descending aortic
dissections into class IIIa, which terminates above ther, please go to www.vasculareducation.com and click on ‘CME’.
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TEVAR for Acute Complicated Aortic Dissection 319diaphragm, and class IIIb, which also involves the abdominal
aorta. The acute phase is defined as the first 2 weeks after
onset because mortality rates are highest during that
time.2,3 The International Registry of Acute Aortic Dissection
(IRAD) has demonstrated that roughly one in three dissec-
tions is of type B.3,4 In acute type A dissection, surgery is the
undisputed treatment, whereas in acute type B dissection,
surgery carries high risks of spinal injury, renal failure and
postoperative mortality.5e7
In uncomplicated, non-traumatic type B dissection,
medical management including aggressive anti-hyperten-
sive medication and alleviation of pain is recommended.1,8
Surgical or interventional treatment is limited to patients
with complicated type B dissection, involving impending
rupture, rapid dilatation, malperfusion or uncontrollable
pain. Since the early reports on the use of stent grafts in
treating aneurysms and dissections of the thoracic
aorta,9e11 several reports have shown the beneficial effects
of thoracic endovascular aortic repair (TEVAR) in acute
complicated type B dissection,12e14 but there still is no
consensus on when to use this method. In addition to
covering the primary intimal tear and stabilising the true
lumen, correction of end-organ malperfusion must also be
undertaken unless branch vessel obstruction is relieved by
TEVAR, and the patients need to be carefully followed up.
The aim of the present study was to investigate the early
and long-term results of our initial 10-year TEVAR experi-
ence of treating patients with complicated acute type B
dissections, with focus on survival, re-intervention rate and
complications. A secondary aim was to analyse whether
outcome differed between DeBakey class IIIa and IIIb
patients.
Materials and Methods
During a 10-year period from the first patient in December
1999 until 31 December 2009, a total of 186 patients
underwent TEVAR. In all, 50 patients were treated for non-
traumatic acute complicated type B dissection. In addition,
10 patients treated for an acute complication occurring
during hospitalisation for the primary aortic dissection
event but >14 days after onset of symptoms were included
in the study group. Thus, in all, 60 patients were followed
up. No patient underwent TEVAR for uncomplicated type B
dissection.
The remaining 126 patients underwent TEVAR for the
following indications: chronic type B dissection with dila-
tation (n Z 22), traumatic aortic transection (n Z 15),
aortic arch/descending aortic aneurysm (n Z 62), thoraco-
abdominal aneurysm (nZ 13), acute type A dissection with
distal malperfusion (n Z 5), chronic type A dissection
(nZ 3), coarctation (nZ 3), mycotic aneurysm (nZ 2) and
aortobronchial fistulae (n Z 1).
Among the 60 patients included, 22 had a DeBakey IIIa
dissection and 38 a IIIb dissection. Median age was 67 years;
33% were women. Median time to treatment from onset of
symptomswas 1.5 days. In the 10 patients treated aftermore
than 14 days, median time was 22 days (range, 15e38 days).
All patients were evaluated by a team of cardiothoracic
and vascular surgeons, interventional radiologists and
anaesthesiologists. Preprocedural imaging was performed
with contrast-enhanced computed tomography (CT). Arterialaccess was established through surgical exposure or percu-
taneously, and the stent grafts were deployed over a stiff
wire.9 A fixed angiographic system was used for the proce-
dure, and transesophageal echocardiography was used to
distinguish the true lumen from the false, and to identify the
entries.
A proximal sealing zone of at least 15 mm was required,
and whenever necessary, the origins of the left subclavian
artery (LSA) and/or the left common carotid artery (CCA)
were covered. Debranching of the CCA was then performed
preprocedurally by an extra-anatomical bypass, while
selective post-procedural revascularisation of the LSA was
undertaken.
Cerebrospinal fluid drainage was used selectively when
the patient was considered to be at increased risk of spinal
cord ischaemia (i.e., most of the descending aorta was to
be excluded (>20 cm) or a history of previous abdominal
aortic repair) or when symptoms of spinal cord ischaemia
occurred. After insertion of the drainage catheter, the
patient was placed in the supine position, and the zero
level of the pressure chamber set at the level of the lumbar
spine, accomplishing passive, continuous drainage. The
drainage was kept for 72 h. In case of progressive neuro-
logical symptoms, active drainage was applied. After
deployment of the stent graft, the mean arterial blood
pressure was kept above 80 mmHg.
Since the introduction of TEVAR, it has been our first-line
therapy in patients with acute complicated type B dissec-
tion. Whenever TEVAR did not relieve malperfusion, addi-
tional branch artery stenting was performed. Two patients,
not in the study group, underwent endovascular fenestra-
tion. No patient underwent branch artery stenting alone,
and no patient underwent open surgical repair.
Follow-up
All patients were prospectively registered. A unique 10-
digit personal identity number (PIN) is allocated to
Swedish citizens and permanent residents. In July 2010,
all these patients were followed up with respect to
survival by computerised cross-linkage to two national
registers: the Swedish Cause of Death Register and the
Population Register. The latter is updated every week,
and there is a maximum delay of 3 weeks from death to
registration. By use of these combined registers, all
patients could be assigned a date of death or identified as
being alive on 30 June 2010. Three patients were neither
Swedish citizens nor residents; two were from the nearby
Finnish island of A˚land, and could be followed up through
their local hospital, whereas one British citizen came back
for a visit 15 months after the procedure, but was then
lost to follow-up.
The patients were followed with CT angiography before
discharge or at 1 month, after 3e6 months, after 12
months, and thereafter annually. In case of endoleak or
expansion, patients underwent angiography, followed by
secondary procedures whenever necessary.
Statistical methods
Continuous variables were summarised with medians and
ranges, and categorical variables with frequencies.
Table 1 Baseline characteristics of patients treated with TEVAR.
Type B dissection DeBakey IIIa (n Z 22) Type B dissection DeBakey IIIb (n Z 38) p value
Women 10 (45%) 10 (26%) 0.16
Median age (range) 73 (55e84) 63 (34e82) 0.002
Hypertension 10 (45%) 23 (61%) 0.28
Diabetes 1 (5%) 0 0.36
Ischaemic heart disease 7 (32%) 5 (13%) 0.10
Peripheral vascular disease 6 (27%) 6 (16%) 0.31
Smoking 10 (45%) 15 (39%) 0.47
320 J. Steuer et al.Categorical data were analysed by Fischer’s exact test; for
age comparisons, the ManneWhitney test was used. The
KaplaneMeier method was applied to calculate life-table
estimates for death and re-intervention. Statistical Package
for Social Sciences (SPSS) for Windows 16.0 was used for
data processing and statistical analyses.
Results
Baseline characteristics are given in Table 1. Patients with
DeBakey IIIa dissection were older than patients with type
IIIb. A high prevalence of hypertension and a large
proportion of smokers was observed in both groups. The
indications for TEVAR are shown in Table 2. Multiple indi-
cations were present in 19 (32%) patients, six of whom were
among the 10, who were treated >14 days after onset of
symptoms. The predominant indication in IIIa patients was
rupture/haematoma/pleural effusion. Distal malperfusion
was barely seen in type IIIa dissections, whereas one or
more vascular beds were affected in 22 (58%) of the 38
patients with IIIb dissections.
The median length of aorta covered by the stent graft
was 20 cm (range, 10e33 cm). In 46 (77%) patients, one
stent graft was used, in 12 patients two stent grafts and in
two patients three stent grafts were used. The Gore TAG
endoprosthesis (WL Gore & Associates, Inc, Flagstaff, AZ,
USA) was used in 54 (90%) patients, and in one combined
with a Relay thoracic stent graft (Bolton Medical, Inc,Table 2 Indication for TEVAR and concomitant procedures in pa
Multiple indications may be present. Number of patients in each
DeBakey IIIa (n
Visceral malperfusion 1
Coeliac trunk stent 0
SMA stent 1
Renal malperfusion 2
Renal artery stent 0
Leg ischaemia 0
Iliac artery stent 1a
Rupture/Haematoma/Pleural effusion 19
Acute dilatation 6
Intractable pain 1
SMA Z Superior Mesenteric Artery.
a Periprocedural rupture, not primary ischaemia.Sunrise, FL, USA). The Relay stent graft was used in one
more patient. The Talent thoracic stent graft was used in
four, and the Valiant thoracic stent graft (Medtronic, Inc,
Minneapolis, MN, USA) in one patient. The stent graft arch
landing zone was Z1 in three patients, Z2 in 30, Z3 in 26 and
Z4 in one patient.15
End-organ complications and concomitant
procedures
Stenting of the true lumen of end-organ arteries was per-
formed in 13 patients. In one patient, the coeliac trunk was
stented (to prevent migration of the thoracic stent graft),
four patients got stents in the superior mesenteric artery
for bowel ischaemia, five patients got renal artery stents
for renal malperfusion and five patients got iliac artery
stents, bilaterally in two. Two patients got both renal and
iliac artery stents (Table 2).
Renal malperfusion was seen in 17 patients. Ten patients
resolved their renal perfusion after TEVAR, and five after an
additional renal artery stent (four left renal artery and one
right). Two patients needed temporary renal replacement
therapy; neither one of them had had a renal artery stent
primarily. One of these patients also developed an abdom-
inal compartment syndrome, secondary to an intestinal
reperfusion syndrome, requiring decompression lapa-
rotomy. The abdomen could be closed on day 13 after
a combination of mesh and vacuum-assisted wound closure.tients with type B dissection in relation to DeBakey subtype.
category are given.
Z 22) DeBakey IIIb (n Z 38) p value
11 0.04
1
3
15 0.02
5
9 0.02
6
15 <0.001
4 0.15
3 1.00
Figure 1 KaplaneMeier survival curves after TEVAR of
complicated type B aortic dissection, subdivided into DeBakey
class IIIa and IIIb, respectively. The number of patients at risk
at different time points after treatment is given.
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for bowel ischaemia, and so did another three patients. Two
of them had had superior mesenteric artery stents.
Twopatients hadan iliac stent graft due to rupture. In three
cases, lower extremity ischaemia necessitated iliac artery
stenting, unilaterally in one, bilaterally in one and one patient
underwent concomitant abdominal aortobiiliac stenting. The
latter also had a femorofemoral crossover bypass, but even-
tually underwent unilateral below-knee amputation.
Neurologic complications and concomitant
procedures
Cervical debranching was carried out in four patients prior
to TEVAR. Three patients underwent right-to-left carotid
crossover bypass and two of them concomitant car-
otidesubclavian bypass to allow stent-graft placement in
the arch; one of these patients had a retrograde dissection.
The fourth patient had a carotidesubclavian bypass done
prior to TEVAR because of the presence of a mammary
arteryecoronary bypass graft. None of these patients had
neurologic complications.
Nine patients had cerebrospinal fluid drainage catheters
inserted prior to TEVAR. None of them had neurologic or
local complications.
A total of seven patients (12%) sustained neurologic
complications; they were all evaluated by a neurologist.
Four patients (7%) had post-procedural spinal ischaemic
symptoms. Two had predominantly unilateral symptoms
(monoplegia), and two had paraplegia. All four got spinal
drainage catheters after onset of symptoms. Three patients
recovered, and one remained paraplegic (2%). Three of the
seven patients showed signs of cerebral lesions. One had
post-procedural right hemiparesis, with a CT-verified left-
sided lacunar infarct; he recovered partially. Another
patient with right hemiparesis had a CT-verified right-sided
lesion, making the interpretation unclear. The third patient
had a left hemiparesis, with a CT-verified right-sided
cerebellar infarction, and the patient recovered.
Two patients had neurologic symptoms on admission.
One had paraplegia with mainly left-leg symptoms, with
concomitant leg ischaemia. After TEVAR and stenting of the
left external iliac artery, he recovered motor function, but
had a remaining impairment of sensibility. The second
patient had partial right hemiplegia, uncontrollable
hypertension and severe distal malperfusion. He died 2 days
after admission from left-hemisphere haemorrhage.
Early and late mortality
There were two early deaths. One died from an intracere-
bral bleeding on the second day and one from multiple
organ failure on day 17 after TEVAR for rupture. Thus, 30-
day mortality was 3%.
Median follow-up time was 3.7 years (interquartile
range, 2.3e5.0 years). Actuarial survival among all patients
was 90%  4% at 3 years, and 87%  5% at 5 years. There was
no survival difference between the two DeBakey subgroups
(log rank, p Z 0.61). Survival curves for patients with
DeBakey type IIIa and IIIb dissections, respectively, are
depicted in Fig. 1.Re-intervention
A total of 19 patients (32%) underwent one or more re-
interventions; five had type IIIa dissection, and 14 type IIIb.
In all, nine patients underwent re-TEVAR. In two patients,
both with type II endoleak, it was done as a secondary re-
intervention after first attempting to remedy the endoleak.
The indication for re-TEVAR was dilatation in all nine. In
three patients, re-TEVAR was combined with cervical
debranching, and in two patients with stenting of the left
renal artery. One patient developed a chronic dissection
with dilatation of the remaining thoraco-abdominal aorta,
and underwent a visceral debranching operation, combined
with stent grafting of both the thoracic and abdominal
aorta. Finally, one patient underwent re-TEVAR without
additional procedures.
Of 28 patients who had their LSA covered without prior
revascularisation, one developed arm claudication, one
rest pain and one subclavian steal syndrome. All three
patients underwent carotidesubclavian bypass, in one it
was combined with percutaneous placement of an
Amplatzer plug in the proximal LSA. Another patient, who
had undergone carotico-carotid and carotidesubclavian
bypass primarily, developed arm claudication due to
stenosis of the right carotid arteryegraft anastomosis and
underwent surgical revision.
Of the remaining six patients needing re-intervention,
two had percutaneous coverage of the LSA, whereby the
endoleak ceased, two patients underwent stent grafting of
one renal artery to cover re-entry sites, in one of these
patients it was combined with EVAR for an aneurysm and
yet another patient underwent EVAR for subsequent dila-
tation. Finally, in one patient, the stent graft had collapsed
in association with operative repair of a later type A
dissection. It was managed by placing Palmaz stents in the
proximal part of the stent graft.
Median time to first re-intervention in the 19 patients
was 0.5 year (range, 1 day to 3.1 years). Actuarial freedom
from re-intervention among all patients was 68%  6% at 3
years and 65%  7% at 5 years. There was no difference
322 J. Steuer et al.(log rank, p Z 0.44) in freedom from re-intervention
between the two DeBakey subgroups (Fig. 2).
Discussion
The present study demonstrated approximately 90% survival
at 3 years and 87% at 5 years after TEVAR in patients with
complicated type B dissections. Malperfused vascular beds
were seen in more than a third of the patients at onset, and
roughly one-fifth of all patients needed adjunctive branch
artery stenting. Distal malperfusion was hardly ever seen in
patients with DeBakey class IIIa dissections, which could be
explained by these dissections ending at the level of the
diaphragm or above. The predominant indication in this
group was imminent rupture. The extension of the dissec-
tion did not affect survival or re-intervention rate.
According to IRAD data,4 3-year survival in patients dis-
charged alive with acute type B dissection was around
75e80% in all three subgroups of medically, surgically and
endovascularly treated patients. Early mortality in TEVAR
patients was 11%. Single-centre studies14,16 and a meta-
analysis12 have reported early mortality rates of 10e25%
after endovascular repair in complicated acute type B
dissection, and 2- and 3-year survivals of 60e73%.13,14,16,17
Thus, survival in this study compares favourably with
previously published results.
In spite of refined surgical technique with neuro-
protective measures, the incidence of perioperative
neurologic complications remains at 5e15% after open
repair.7,18 After TEVAR, lower incidences of spinal and
cerebral complications have been reported than after
surgery.12,13,17,18 The use of the combination of endovas-
cular flap fenestration and branch artery stenting in
patients presenting with malperfusion is an alternative
means to restore end-organ perfusion used by some centres,
with a reported incidence of neurologic complications at
the same magnitude as after TEVAR.19 However, fenestra-
tion cannot be used to treat rupture or dilatation.19,20Figure 2 KaplaneMeier curves of freedom from re-
intervention after TEVAR of complicated type B aortic dissec-
tion, subdivided into DeBakey class IIIa and IIIb, respectively.
The number of patients at risk at different time points after
treatment is given.The incidence of neurologic events, 7 out of 60 patients
(12%), was fairly high. Another two patients had severe
neurologic impairment on admission. However, three
of four patients with spinal ischaemia and one of the
patients with a new cerebral ischaemic lesion recovered
completely. The incidence of permanent neurologic
damage was similar to other reports.12,13,21 All patients,
who developed spinal symptoms, received a cerebrospinal
fluid drain shortly after onset, and were monitored in the
intensive care unit. We cannot tell whether or not they
might have recovered without drainage, but none of the
patients who received a drain prior to TEVAR had any
neurologic symptoms. Spinal drain is now used more
frequently in our TEVAR patients.
Approximately one-third of the patients needed re-
intervention, half of them had re-TEVAR and half had
adjunctive procedures. Previous reports have addressed
potential mechanisms of remodelling and expansion after
TEVAR for acute complicated type B dissection.12,16 The
recent development of more flexible stent grafts may help
prevent some cases of proximal type I endoleak. We have
modified our technique in that we now routinely deploy the
stent graft at the level of the LSA, even in case of a more
distal primary intimal tear.
In this report, we included 10 patients with complicated
type B dissections, who were still hospitalised after the
primary event. They were treated because of acute
complications, with multiple complications present in six of
them, indicating that these patients differed from other
chronic dissection patients, who are commonly treated for
progressive dilatation. As the original 2-week definition was
based on a mixed type A and type B cohort with many
patients left untreated, we believe that this arbitrary time
limit could be questioned; it may take longer than 2 weeks
for a dissection to stabilise.
We conclude that TEVAR in patients with complicated
acute type B dissection was associated with few permanent
neurologic complications and excellent long-term survival.
TEVAR was often sufficient to relieve malperfusion, but
immediate concomitant procedures were sometimes
necessary, as well as later re-interventions. These patients
require careful post-procedural surveillance, both in the
early and late stages. Until results of further studies are
reported, endovascular therapy of the thoracic aorta
should be confined to large centres with post-procedural
follow-up, as well as scientific evaluation of the results.
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